Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Charlotte’s Web Holdings ( (TSE:CWEB) ) just unveiled an update.
DeFloria Inc., a botanical pharmaceutical developer spun out of Charlotte’s Web’s founders, is advancing its lead cannabinoid-based drug candidate AJA001, an oral solution for irritability associated with autism spectrum disorder, through the FDA’s botanical drug pathway. Positioned as one of the most advanced cannabinoid programs in this regulatory track, DeFloria has a cleared investigational new drug application, completed a Phase 1 safety and pharmacokinetic/pharmacodynamic trial, and secured authorization to initiate Phase 2 clinical studies. The company says the Presidential Executive Order reclassifying cannabis from Schedule I to Schedule III validates its long-standing strategy and places it years ahead of competitors, as federal recognition of cannabinoids’ medical use is expected to unlock expanded research funding, academic collaborations, institutional capital, and pharmaceutical partnerships—potentially accelerating development of approved cannabinoid therapies and strengthening DeFloria’s role at the forefront of this emerging drug class.
The most recent analyst rating on (TSE:CWEB) stock is a Hold with a C$0.28 price target. To see the full list of analyst forecasts on Charlotte’s Web Holdings stock, see the TSE:CWEB Stock Forecast page.
Spark’s Take on TSE:CWEB Stock
According to Spark, TipRanks’ AI Analyst, TSE:CWEB is a Neutral.
The overall stock score is primarily impacted by the company’s weak financial performance, characterized by declining revenues and profitability issues. While technical analysis shows bullish momentum, overbought conditions suggest caution. The valuation is poor due to negative earnings and lack of dividends, further weighing down the score.
To see Spark’s full report on TSE:CWEB stock, click here.
More about Charlotte’s Web Holdings
DeFloria Inc. is an FDA Phase 2 clinical-stage botanical pharmaceutical company formed in 2023 by AJNA BioSciences PBC and Charlotte’s Web Holdings. The company develops cannabinoid-based botanical drugs, led by its AJA001 oral solution targeting irritability associated with autism spectrum disorder, and leverages Charlotte’s Web’s legacy in CBD and real-world cannabinoid health data to pursue FDA-regulated botanical drug pathways.
Average Trading Volume: 186,083
Technical Sentiment Signal: Buy
Current Market Cap: C$35.07M
See more data about CWEB stock on TipRanks’ Stock Analysis page.